The first randomized, placebo-controlled parallel study of theaflavins on lipid levels of individuals with hypercholesterolemia was performed by Nashai Biotech LLC.
The hypothesis was that theaflavins not only significantly lower LDL cholesterol, the “bad cholesterol”, in adults with high LDL cholesterol, but is free of side effects. Although further research is needed to fully elucidate the mechanisms of action of theaflavins in lowering LDL, the outcomes of the study substantiated the hypothesis.
Choleve(the source of concentrated theaflavin)in capsule form as well as a placebo capsule were administered in exactly the same fashion to separate groups and were tracked using the same testing and the same indicators. Study participants that received theaflavins capsules (Choleve) compared to those who took placebos showed 11.3 percent decreased serum total cholesterol and 16.4 percent reduced serum LDL-C, the bad cholesterol.
Comparing the two test groups mean percentage change in the following areas, the theaflavins group’s mean levels of TC, TG, HDL and LDL changed by 11.3 percent, 2.6 percent, 23 percent, and 16.4 percent respectively. The placebo group’s mean levels of TC, TG, HDL and LDL changed by 0.7 percent, 5.6 percent, 0.7 percent, and 0.26 percent.